The Division of Oncology and Hematology (ONC HEM) has a long tradition of pioneering research in the field of cancer and its treatment. There are numerous ongoing state-of-the art clinical trials that are available to patients with various cancers. The Division has been a main member of the Cancer and Leukemia Group B (CALGB) for Non-Institutional Cooperative trials since 1996, now renamed the Alliance for Clinical Trials in Oncology (Alliance). Alliance is one of four multidisciplinary cooperative adult cancer treatment groups funded by the National Cancer Institute (NCI). Each Non-Institutional cooperative group trial focuses on particular areas of cancer research, often collaborating in large-scale clinical trials.
The Division of ONC HEM is also an active national Research Reporting Center to the Center for International Blood and Marrow Transplant Research (CIBMTR, formerly IBMTR/ABMTR). The CIBMTR holds the contract for the Stem Cell Therapeutic Outcomes Database (SCTOD) Health Resources and Service Administration of the US Dept. of Health and Human Services (HRSA). CIBMTR is charged with collecting our institutions Center program data on all allogeneic hematopoietic cell transplantations performed in the United States under Federal Law. CIBMTR forms a research collaboration with the National Marrow Donor Program (NMDP) and the Blood and Marrow Transplant Clinical Trial Network (BMT CTN) to facilitate observational and interventional research outcomes through a large network of transplant centers. The BMT CTN is funded by the NCI and is a network of transplant institutions/consortia in the United States actively recruiting patients to various clinical protocols in bone marrow and hematopoietic stem cell transplantation (HSCT).
The Division is a member in the Big Ten Cancer Research Consortium (BTCRC). The Big Ten Cancer Research Consortium is a consortium comprising of the Big Ten universities (Sponsor Investigators) that create a unique team culture to pre-screen large populations in order to identify small, molecularly-enriched subsets. The Division is very active in various Industrial (Pharmaceutical), Non-Intervention and Institutional Investigator-Initiated clinical research trials conducted with NIH Clinical Research Trials around the world.
The Oncology and Hematology Division is also known for the establishment of the Nebraska Lymphoma Study Group (NLSG).
Additionally, all faculty members of the Division participate in the various programs/studies conducted within the Fred & Pamela Buffet Cancer Center.